News | November 01, 2024
AstraZeneca China President currently under investigation
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Strengthening focus in Alzheimer's disease and neuroscience pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
Subscribe To Our Newsletter & Stay Updated
